Assessment of Candidate Loci in Neurological diseases
$728,868Z01FY2007AGNIH
Aging
Investigators
Linked publications & trials
Paper 25653294Paper 25281017Paper 25124890Paper 22806825Paper 22721568Paper 22488858Paper 22326202Paper 22323751Paper 21875901Paper 21601954Paper 20837969Paper 20683486Paper 20551478Paper 20437544Paper 20399836Paper 20034704Paper 19846850Paper 19571725Paper 19489756Paper 19475667Paper 19351622Paper 19286695Paper 19205068Paper 19202559Paper 19165922Paper 19063963Paper 19021754Paper 18942080Paper 18927607Paper 18545701Paper 18435766Paper 18395980Paper 18364387Paper 18337587Paper 18311830Paper 18213618Paper 18211709Paper 18160183Paper 18098275Paper 18044725Paper 17625107Paper 17622782Paper 17485640Paper 17371905Paper 17133500Paper 17080433Paper 16781064Paper 16685660Paper 16511860Paper 16467219Paper 16261622Paper 16257123Paper 16157901Paper 16102903Paper 16078202Paper 15967032Paper 15924299Paper 15911147Paper 15852391Paper 15852366Paper 15773923Paper 15732108Paper 15680457Paper 15680455Paper 15642852Paper 15641013Paper 15635662Paper 15596610Paper 15490287Paper 15464261Paper 15331145Paper 15304594Paper 15254940Paper 15254937Paper 15197699Paper 15172093Paper 15159488Paper 14981185Paper 14978684Paper 14976159Paper 14736756Paper 14625045Paper 14593171Paper 14557580Paper 12891685Paper 12853230Paper 12849210Paper 12730580Paper 12720091Paper 12671950Paper 12465073Paper 12411758Paper 12360561
Abstract
During the past year we have focussed much of our efforts on identifying the extent and nature of LRRK2 mutation and variation. This work has been performed primarily in Parkinsons disease patients. Unlike most protocols we have taken a full screening approach, sequencing all 51 coding exons of LRRK2. In addition we have continued assessment of PARK2, PARK6, PARK7, GCH1, SNCA and TOR1A in both Parkinsons disease and dystonia. This work has lead to the identification of several novel mutations.
View original record on NIH RePORTER →